Infectious Disease and Microbiology - Bordetella bronchiseptica

Basics

Bordetella bronchiseptica is an aerobic Gram-negative bacillus that primarily colonizes and infects the respiratory tracts of animals. Human infection is uncommon, but when it occurs it most often involves the respiratory system and may be more severe in immunocompromised patients or those with chronic lung disease.

Unlike Bordetella pertussis, which is a major human respiratory pathogen, B. bronchiseptica is principally a zoonotic organism.

Microbiologic Characteristics

Bordetella bronchiseptica is:

• Gram negative

• Bacillary in shape

• Aerobic

It belongs to the genus Bordetella, but its antimicrobial susceptibility pattern differs importantly from that of B. pertussis.

Epidemiology

The organism has a worldwide distribution.

It is commonly associated with animals, particularly mammals with respiratory tract colonization or infection. Human disease is rare and usually sporadic.

Exposure to infected or colonized animals may be relevant in some cases.

Risk Factors

Human infection is more likely in patients with:

• Immunosuppression

• Chronic pulmonary disease

• Structural lung abnormalities

• Frequent animal exposure

• Severe underlying illness

Although healthy individuals can occasionally be infected, clinically significant disease is more often reported in vulnerable hosts.

Clinical Infections

Pneumonia

Pneumonia is one of the most important manifestations of B. bronchiseptica infection.

Possible symptoms include:

• Fever

• Cough

• Sputum production

• Dyspnea

• Pleuritic discomfort

• Hypoxemia in severe disease

The infection may resemble other bacterial pneumonias and therefore requires microbiologic confirmation.

Tracheobronchitis

The organism may also cause tracheobronchial infection.

Patients may develop:

• Persistent cough

• Increased respiratory secretions

• Wheezing

• Chest discomfort

• Fever

This may be especially important in patients with preexisting respiratory disease.

Bacteremia

Although uncommon, B. bronchiseptica can invade the bloodstream.

Bacteremia is more likely in:

• Immunocompromised patients

• Patients with severe pulmonary infection

• Patients with major underlying disease

Clinical findings may include:

• Fever

• Chills

• Hypotension

• Sepsis in severe cases

Diagnosis

Diagnosis is primarily established by:

Culture

Depending on the clinical syndrome, specimens may include:

• Sputum

• Bronchoalveolar lavage fluid

• Tracheal secretions

• Blood cultures

Because the organism is unusual in humans, laboratory identification is important to distinguish it from other Bordetella species and from other Gram-negative respiratory pathogens.

Treatment

A key therapeutic point is that B. bronchiseptica differs from B. pertussis.

Macrolide Resistance

In contrast to B. pertussis, B. bronchiseptica is often resistant to macrolides.

Therefore, agents such as:

• Azithromycin

• Clarithromycin

• Erythromycin

should not automatically be assumed to be effective.

Antipseudomonal Beta-Lactams

Antipseudomonal beta-lactam agents are often active.

Potential options may include agents with activity against resistant Gram-negative bacilli, depending on susceptibility results.

Definitive therapy should ideally be guided by antimicrobial susceptibility testing.

Additional Treatment Options

Other potentially active agents include:

• Aminoglycosides

• Imipenem

• Doxycycline

The choice depends on the severity of infection, site involved, renal function, and susceptibility profile.

Severe Infection

For pneumonia with bacteremia or other invasive disease, intravenous therapy is generally appropriate initially.

Management should also include:

• Oxygen support when needed

• Fluid management

• Treatment of sepsis

• Evaluation of underlying immunosuppression

• Repeat cultures if bacteremia persists

Differential Diagnosis

Respiratory infection due to B. bronchiseptica may resemble:

• Bordetella pertussis

• Pseudomonas aeruginosa

• Haemophilus influenzae

• Enteric Gram-negative pneumonia

• Other bacterial causes of tracheobronchitis

A zoonotic exposure history and culture identification help distinguish the organism.

Prevention

Because human infection is uncommon, there are no routine human vaccination recommendations specifically for B. bronchiseptica.

General preventive measures include:

• Careful hygiene after animal contact

• Avoiding close exposure to sick animals when severely immunocompromised

• Appropriate veterinary care for infected animals

• Standard infection-control practices in healthcare environments

High-Yield Clinical Pattern

Immunocompromised patient

• ●

Animal exposure

• ●

Pneumonia or tracheobronchitis

• ●

Gram-negative Bordetella isolated in culture

→ Consider Bordetella bronchiseptica

High-Yield Treatment Distinction

B. pertussis

→ Macrolides commonly used

B. bronchiseptica

→ Often macrolide resistant

→ Antipseudomonal beta-lactams, imipenem, doxycycline, or aminoglycosides may be active

Exam Essentials

Organism:

→ Bordetella bronchiseptica

Microbiology:

→ Aerobic Gram-negative bacillus

Distribution:

→ Worldwide

Major infections:

→ Pneumonia, tracheobronchitis, bacteremia

Important host:

→ Often immunocompromised or chronically ill patients

Diagnosis:

→ Culture

Key antimicrobial distinction:

→ Often resistant to macrolides

Commonly active therapy:

→ Antipseudomonal beta-lactam

Other possible agents:

→ Aminoglycosides, imipenem, doxycycline

Key clinical pearl: Unlike B. pertussis, B. bronchiseptica should not be assumed to respond to macrolides; susceptibility-guided therapy is important.